SAFETY DATA SHEET

Lisinopril / Hydrochlorothiazide Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Lisinopril / Hydrochlorothiazide Formulation

Manufacturer or supplier's details
Company : MSD
Address : Avenida Tanner de Melo, Quadra 10 Lote 4A, Galpão A Parque Industrial Vice Presidente José Alencar Aparecida de Goias – GO, Brazil
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard
Reproductive toxicity : Category 1A
Specific target organ toxicity - repeated exposure : Category 1 (Kidney, Parathyroid gland)

GHS label elements in accordance with ABNT NBR 14725 Standard
Hazard pictograms :

Signal Word : Danger

Hazard Statements : H360D May damage the unborn child.
H372 Causes damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

Precautionary Statements :
Prevention:
P201 Obtain special instructions before use.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
SAFETY DATA SHEET

Lisinopril / Hydrochlorothiazide Formulation

Storage:
P405 Store locked up.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form combustible dust concentrations in air during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td></td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>58-93-5</td>
<td>Acute toxicity (Oral), Category 5 Specific target organ toxicity - repeated exposure (Kidney, Parathyroid gland), Category 1</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>83915-83-7</td>
<td>Reproductive toxicity, Category 1A Specific target organ toxicity - repeated exposure (Oral) (Kidney), Category 2</td>
<td>&gt;= 5 - &lt; 10</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and : May damage the unborn child.
Causes damage to organs through prolonged or repeated
SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NOx)
Chlorine compounds
Sulfur oxides
Metal oxides
Oxides of phosphorus

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and
disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust, fume, gas, mist, vapors or spray. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters
Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
---|---|---|---|---|
Starch | 9005-25-8 | TWA | 10 mg/m³ | ACGIH |
Hydrochlorothiazide | 58-93-5 | TWA | 100 µg/m³ (OEB 2) | Internal |
Lisinopril | 83915-83-7 | TWA | 20 µg/m³ (OEB 3) | Internal |

Engineering measures: Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type
Hand protection Material: Chemical-resistant gloves

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: solid
Color: No data available
Odor: odorless
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: Not applicable
Flammability (solid, gas): May form combustible dust concentrations in air during processing, handling or other means.
### SECTION 10. STABILITY AND REACTIVITY

**Reactivity**: Not classified as a reactivity hazard.

**Chemical stability**: Stable under normal conditions.

**Possibility of hazardous reactions**:
- May form combustible dust concentrations in air during processing, handling or other means.
- Can react with strong oxidizing agents.

**Conditions to avoid**:
- Heat, flames and sparks.
- Avoid dust formation.

**Incompatible materials**:
- Oxidizing agents

**Hazardous decomposition products**: No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

**Information on likely routes of**: Inhalation
SAFETY DATA SHEET
Lisinopril / Hydrochlorothiazide Formulation

exposure
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg
Method: Calculation method

Components:
Starch:
Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg
Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Hydrochlorothiazide:
Acute oral toxicity : LD50 (Rat): > 2.750 mg/kg
LD50 (Mouse): > 2.830 mg/kg
Acute toxicity (other routes of administration) : LD50 (Rat): 990 mg/kg
Application Route: Intravenous
LD50 (Mouse): 590 mg/kg
Application Route: Intravenous

Lisinopril:
Acute oral toxicity : LD50 (Rat): > 20.000 mg/kg
LD50 (Mouse): > 20.000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
Hydrochlorothiazide:
Species : Rabbit
Result : No skin irritation

Lisinopril:
Species : Rabbit
Result : Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.
Components:

Starch:
Species: Rabbit
Result: No eye irritation

Hydrochlorothiazide:
Species: Rabbit
Result: Mild eye irritation

Lisinopril:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Starch:
Test Type: Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative

Lisinopril:
Test Type: Maximization Test
Routes of exposure: Dermal
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

Starch:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Hydrochlorothiazide:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative
SAFETY DATA SHEET

Lisinopril / Hydrochlorothiazide Formulation

Version: 2.4  
Revision Date: 10.10.2020  
SDS Number: 4573754-00008  
Date of last issue: 13.04.2020  
Date of first issue: 08.07.2019

Test Type: sister chromatid exchange assay  
Test system: Chinese hamster ovary cells  
Result: positive

Test Type: in vitro test  
Test system: mouse lymphoma cells  
Result: positive

Genotoxicity in vivo:

Test Type: Chromosomal aberration  
Species: Chinese hamster  
Cell type: Bone marrow  
Result: negative

Test Type: in vivo assay  
Species: Mouse  
Cell type: Bone marrow  
Result: negative

Germ cell mutagenicity - Assessment:

Weight of evidence does not support classification as a germ cell mutagen.

Lisinopril:

Genotoxicity in vitro:

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Alkaline elution assay  
Test system: rat hepatocytes  
Result: negative

Genotoxicity in vivo:

Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Carcinogenicity:

Not classified based on available information.

Components:

Hydrochlorothiazide:

Species: Mouse, female  
Application Route: Oral  
Exposure time: 2 Years  
Result: negative

Species: Mouse, male  
Application Route: Oral  
Exposure time: 2 Years  
Result: equivocal
SAFETY DATA SHEET

Lisinopril / Hydrochlorothiazide Formulation

Species: Rat, male and female
Application Route: Oral
Exposure time: 2 Years
Result: negative

Lisinopril:
Species: Rat
Application Route: Oral
Exposure time: 105 weeks
NOAEL: 90 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 92 weeks
NOAEL: 135 mg/kg body weight
Result: negative

Reproductive toxicity
May damage the unborn child.

Components:

Hydrochlorothiazide:
Effects on fertility: Test Type: Fertility
Species: Rat, male and female
Application Route: oral (feed)
Fertility: NOAEL: 4 mg/kg body weight
Result: Effects on fertility.

Species: Mouse, male and female
Application Route: oral (feed)
Fertility: NOAEL: 100 mg/kg body weight
Result: Effects on fertility.

Effects on fetal development: Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 3.000 mg/kg body weight
Result: No teratogenic effects.

Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 1.000 mg/kg body weight
Result: No teratogenic effects.

Lisinopril:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 300 mg/kg body weight
Symptoms: No effects on mating performance. Result: Animal testing did not show any effects on fertility.

Effects on fetal development:
- Test Type: Development
- Species: Rat
- Application Route: Oral
- Developmental Toxicity: LOAEL: 30 mg/kg body weight
- Result: positive, No teratogenic effects.

- Test Type: Development
- Species: Mouse
- Application Route: Oral
- Developmental Toxicity: LOAEL: 100 mg/kg body weight
- Symptoms: Total Resorptions / resorption rate.
- Result: Embryotoxic effects and adverse effects on the offspring were detected.

- Test Type: Development
- Species: Rabbit
- Application Route: Oral
- Developmental Toxicity: LOAEL: 0,1 mg/kg body weight
- Result: Embryotoxic effects and adverse effects on the offspring were detected.

Reproductive toxicity - Assessment:
Positive evidence of adverse effects on development from human epidemiological studies.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Causes damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

Components:

Hydrochlorothiazide:
- Target Organs: Kidney, Parathyroid gland
- Assessment: Causes damage to organs through prolonged or repeated exposure.

Lisinopril:
- Routes of exposure: Ingestion
- Target Organs: Kidney
- Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Starch:
- Species: Rat
- NOAEL: >= 2.000 mg/kg
- Application Route: Skin contact
## Expiration time
28 Days

## Method
OECD Test Guideline 410

### Hydrochlorothiazide:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat, male and female</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>2 y</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney, Parathyroid gland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse, male and female</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>300 - 550 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>2 y</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>9 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Parathyroid gland</td>
</tr>
</tbody>
</table>

### Lisinopril:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>&lt; 3.650 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>1 y</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>&lt; 840 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>4 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

### Aspiration toxicity
Not classified based on available information.

## Components:

### Hydrochlorothiazide:
No aspiration toxicity classification

## Experience with human exposure

### Components:

### Hydrochlorothiazide:

<table>
<thead>
<tr>
<th>Mode</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye contact</td>
<td>Eye irritation</td>
</tr>
<tr>
<td>Ingestion</td>
<td>Dizziness, Headache, Fatigue, Nausea, Abdominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain</td>
</tr>
</tbody>
</table>
Lisinopril / Hydrochlorothiazide Formulation

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

**Components:**

**Hydrochlorothiazide:**

Toxicity to fish

- LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l
  Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates

- EC50 (Daphnia magna (Water flea)): > 500 mg/l
  Exposure time: 48 h

**Lisinopril:**

Toxicity to daphnia and other aquatic invertebrates

- EC50 (Daphnia magna (Water flea)): 20,000 mg/l
  Exposure time: 48 h
  Method: OECD Test Guideline 202

Persistence and degradability

**Components:**

**Hydrochlorothiazide:**

Stability in water

- Hydrolysis: 46.2 % (96 h)

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

**Disposal methods**

- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
  If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

**International Regulations**

UNRTDG
SAFETY DATA SHEET

Lisinopril / Hydrochlorothiazide Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.4</td>
<td>10.10.2020</td>
<td>4573754-00008</td>
<td>13.04.2020</td>
<td>08.07.2019</td>
</tr>
</tbody>
</table>

Not regulated as a dangerous good

**IATA-DGR**
Not regulated as a dangerous good

**IMDG-Code**
Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
Not applicable for product as supplied.

**Domestic regulation**

**ANTT**
Not regulated as a dangerous good

### SECTION 15. REGULATORY INFORMATION

**Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH)

Group 2B: Possibly carcinogenic to humans
Hydrochlorothiazide 58-93-5

Brazil. List of chemicals controlled by the Federal Police: Not applicable

**International Regulations**

The ingredients of this product are reported in the following inventories:

- **AICS**: not determined
- **DSL**: not determined
- **IECSC**: not determined

### SECTION 16. OTHER INFORMATION

**Further information**


**Full text of other abbreviations**

- **ACGIH**: USA. ACGIH Threshold Limit Values (TLV)
- **ACGIH / TWA**: 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.